<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699010</url>
  </required_header>
  <id_info>
    <org_study_id>AP-ADF-111</org_study_id>
    <nct_id>NCT00699010</nct_id>
  </id_info>
  <brief_title>Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse</brief_title>
  <official_title>A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acura Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acura Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual
      recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40
      mg alone in subjects with a history of opioid abuse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Treatment Phase, subjects randomly received oxycodone HCl 40 mg administered in
      combination with niacin 240 mg and oxycodone HCl 40 mg alone in crossover design. 15 subjects
      were randomized to receive oxycodone/niacin first followed by oxycodone with a 48 hour
      washout between doses. 15 subjects randomized to receive oxycodone before the
      oxycodone/naicin dose with a 48 hour washout between doses. The purpose of the Treatment
      Phase was to assess the abuse liability and abuse deterrence potential of 4 times the
      recommended 2-tablet dose of AcuroxÂ® Tablets 5/30 mg versus oxycodone HCl 40 mg alone (8
      tablets per dose).

      All 30 subjects received a single dose of each study treatment. Subjects were fasted prior to
      dosing on all dose days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min)</measure>
    <time_frame>Effects assessed at 0.5 hours after dosing.</time_frame>
    <description>&quot;Do you dislike or like the drug effect you are feeling now?&quot; This question was rated on a 1 to 29 point VAS scale that was anchored in the center with &quot;neither like nor dislike&quot; (14), on the left with &quot;dislike an awful lot&quot; (1), and on the right with &quot;like an awful lot&quot; (29).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>Acurox 5/30mg taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone 5mg taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxycodone HCl 5mg tablets; 8 tablets per dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acurox 5/30mg taken first</intervention_name>
    <description>followed by oxycodone 5mg with 48 hour washout</description>
    <arm_group_label>Acurox 5/30mg taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 5mg taken first</intervention_name>
    <description>followed by Acurox 5/30mg with 48 hour washout</description>
    <arm_group_label>Oxycodone 5mg taken first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female between 18 and 55 years of age

          -  Subject meets DSM-IV Criteria for the Diagnosis of Opioid Substance Abuse and subject
             is unlikely to experience an idiosyncratic reaction or respiratory depression after
             ingesting 40 mg of oxycodone

          -  Body weight is not more than 20% above or below ideal body weight

          -  Subject agrees to abstain from any Rx or OTC drugs (except as authorized by the
             Investigator) or alcohol

          -  Subject is in generally good health

          -  Subject is reliable, willing, cooperative, able to communicate effectively, and has a
             minimum of a 6th grade reading level

          -  Subject has an acceptable score on the MMSE for cognitive impairment

          -  For women of child-bearing potential: woman is not pregnant and not nursing, and is
             practicing an acceptable method of birth control

        Exclusion Criteria:

          -  Subject has a disease that may endanger the subject or the validity of the data

          -  Subject is currently physically dependent on opiates or alcohol

          -  Subject was exposed to any investigational drug within 30 days prior to the inpatient
             phase

          -  Subject has a history of hypersensitivity to any drug, or a known allergy to any
             component of the study drug formulation

          -  Subject has a positive urine drug screen for a non-opiate drug

          -  Subject has a predisposing condition that may place the subject at risk for receiving
             niacin or oxycodone, or confound the study analyses

          -  Subject ingested niacin at doses higher than SDI within 14 days prior to the inpatient
             phase

          -  Subject has an abnormal bleeding tendency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald R Jasinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>September 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2018</results_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abuse Liability</keyword>
  <keyword>Abuse Prevention</keyword>
  <keyword>Abuse Resistance</keyword>
  <keyword>Abuse Deterrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acurox 5/30mg Taken First</title>
          <description>Oxycodone HCl/Niacin 5/30mg; 8 tablet dose followed by oxycodone 5mg with 48 hour washout</description>
        </group>
        <group group_id="P2">
          <title>Oxycodone 5mg Taken First</title>
          <description>Oxycodone Hcl 5mg; 8 tablet dose follwed by Acurox 5/30mg with 48 hour washout</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Recreational Drug Abusers</population>
      <group_list>
        <group group_id="B1">
          <title>Acurox 5/30mg Taken First</title>
          <description>Oxycodone HCL/Niacin 5/30mg; 8 tablet dose followed by Oxycodone 5mg with 48 hour washout</description>
        </group>
        <group group_id="B2">
          <title>Oxycodone 5mg Taken First</title>
          <description>Oxycodone HCL 5mg; 8 tablet dose followed by Acurox 5/30mg with 48 hour washout</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="5.5"/>
                    <measurement group_id="B2" value="44.7" spread="5.5"/>
                    <measurement group_id="B3" value="44.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min)</title>
        <description>&quot;Do you dislike or like the drug effect you are feeling now?&quot; This question was rated on a 1 to 29 point VAS scale that was anchored in the center with &quot;neither like nor dislike&quot; (14), on the left with &quot;dislike an awful lot&quot; (1), and on the right with &quot;like an awful lot&quot; (29).</description>
        <time_frame>Effects assessed at 0.5 hours after dosing.</time_frame>
        <population>Study completers and per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Acurox 5/30mg</title>
            <description>Oxycodone HCL/Niacin 5/30mg; 8 tablet dose</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone 5mg</title>
            <description>Oxycodone 5mg; 8 tablet dose</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min)</title>
          <description>&quot;Do you dislike or like the drug effect you are feeling now?&quot; This question was rated on a 1 to 29 point VAS scale that was anchored in the center with &quot;neither like nor dislike&quot; (14), on the left with &quot;dislike an awful lot&quot; (1), and on the right with &quot;like an awful lot&quot; (29).</description>
          <population>Study completers and per protocol</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="1.0"/>
                    <measurement group_id="O2" value="14.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 days. Doses taken 1 per day with a 48 hours washout</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acurox 5/30mg</title>
          <description>Oxycodone HCL/Niacin 5/30mg; 8 tablet dose</description>
        </group>
        <group group_id="E2">
          <title>Oxycodone 5mg</title>
          <description>Oxycodone HCl 5mg; 8 tablet dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoria</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="30"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <description>Flushing</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ron Spivey</name_or_title>
      <organization>Acura Pharma</organization>
      <phone>847-705-7709</phone>
      <email>rspivey@acurapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

